Trials / Completed
CompletedNCT02722941
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and tolerability of LBH589 maintenance therapy after autologous hematopoietic cell transplant (HCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panobinostat | Maintenance therapy dosing as outlined in Cohorts A and B. |
Timeline
- Start date
- 2016-06-10
- Primary completion
- 2020-06-07
- Completion
- 2021-01-18
- First posted
- 2016-03-30
- Last updated
- 2022-11-01
- Results posted
- 2021-08-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02722941. Inclusion in this directory is not an endorsement.